BioSenic SA Logo

BioSenic SA

Developing ATO and cell therapies for autoimmune diseases and tissue regeneration.

BIOS | BR

Overview

Corporate Details

ISIN(s):
BE0970179827 (+1 more)
LEI:
549300HFIIMTOP1DFR76
Country:
Belgium
Address:
RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BioSenic SA is a biotechnology company focused on developing innovative clinical-stage therapies for autoimmune diseases and regenerative medicine. The company's pipeline is centered on two main platforms: a novel treatment using arsenic trioxide (ATO) to target the underlying causes of autoimmune and inflammatory conditions, and an allogeneic cell therapy platform aimed at tissue repair and organ regeneration. Formerly known as Bone Therapeutics, BioSenic combines its expertise in immunomodulation and cell therapy to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 10:00
Regulatory News Service
BioSenic SA_Proxy EGM_FR_OC draft 2025 11 07(1518280.1).pdf
French 322.9 KB
2025-11-12 10:00
Regulatory News Service
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-11-12 10:00
Regulatory News Service
BioSenic SA_Convening notice_2025_FR_2025 11 04(1506176.1).pdf
French 302.6 KB
2025-11-12 10:00
Regulatory News Service
BioSenic SA_ Information on shareholders' rights EGM_FR_2025 11 07(1506226.1).p…
French 152.9 KB
2025-11-12 10:00
Regulatory News Service
BIOS_PR_GMs-2025_FR_2025 11 07(1506246.1).pdf
French 214.9 KB
2025-11-12 10:00
Regulatory News Service
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-11-12 10:00
Regulatory News Service
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-10-28 07:00
Interim Report
BIOS_H1-PR Report_FR_2025 10 28_final.pdf
French 371.5 KB
2025-09-29 22:00
Pre-Annual General Meeting Information
BioSenic SA_ Information on shareholders' rights GMs_FR_2025 09 29.pdf
French 160.6 KB
2025-09-29 22:00
Share Issue/Capital Change
BioSenic - (FR) Warrant_Plan - 2025 09 29.pdf
French 316.3 KB
2025-09-29 22:00
Management Discussion and Analysis
BioSenic - Rapport de gestion - 20250929-final.pdf
French 616.8 KB
2025-09-29 22:00
Audit Report / Information
BioSenic SA-rapport du commissaire-31 12 2024_signed.pdf
French 1.6 MB
2025-09-29 22:00
Management Discussion and Analysis
BioSenic___Rapport_spécial_CA_(Art_7_228_CSA)_2025_09_29.docx.pdf
French 348.2 KB
2025-09-29 22:00
Annual Report
20250817_Rapport annuel 2024_FR_Final.pdf
French 2.0 MB
2025-09-29 22:00
Proxy Solicitation & Information Statement
BioSenic SA_Proxy AGM_FR_2025 09 29.pdf
French 422.0 KB

Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioSenic SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioSenic SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-16 Rieger Francois Board Sell 2,500,000 25,000.00 EUR
2024-08-06 Rieger Francois Board Sell 868,653 7,186.87 EUR
2024-08-05 POMI SCHNEITER VERONIQUE Board Sell 534,750 4,331.47 EUR
2024-08-02 POMI SCHNEITER VERONIQUE Board Sell 193,900 1,609.37 EUR
2024-08-01 Rieger Francois Board Sell 1,236,684 11,463.87 EUR
2024-08-01 POMI SCHNEITER VERONIQUE Board Sell 140,003 1,246.03 EUR
2024-07-31 POMI SCHNEITER VERONIQUE Board Sell 503,771 4,685.07 EUR
2024-07-30 POMI SCHNEITER VERONIQUE Board Sell 360,021 3,348.20 EUR
2024-07-29 POMI SCHNEITER VERONIQUE Board Sell 372,893 3,430.62 EUR
2024-07-24 POMI SCHNEITER VERONIQUE Board Sell 2,168,361 21,033.10 EUR

Peer Companies

Acrivon Therapeutics, Inc. Logo
Develops precision cancer therapies by matching patients to drugs using its proteomics platform.
United States of America
ACRV
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France
ALACT
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing an antibody therapy for Alzheimer's by targeting toxic AβOs.
United States of America
ABOS
Adaptive Biotechnologies Corp Logo
Maps immune genetics for blood cancer diagnostics and drug discovery partnerships.
United States of America
ADPT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland
ADI1
Adeia Inc. Logo
Invents and licenses foundational IP for the media and semiconductor industries.
United States of America
ADEA
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea
397810
Aditxt, Inc. Logo
Acquires and develops biotech for autoimmunity, cancer detection, and neuro diagnostics.
United States of America
ADTX
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France
ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany
APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.